David Brosman, MD
Interventional Pain Medicine · Hilton Head, SCNPI 1023113008
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 142 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by Abbott at 37.4% of the total. Reporting peaked in 2019 at $1,503 and has fallen 90.8% since, to $138 in 2025.
Across 142 payments — averaging $28.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$547
- Medtronic$426
- Flowonix Medical Incorporated$362
- Nevro Corp.$296
- Tersera Therapeutics LLC$206
- plus $672 from 20 others
What the payments were for
- Food & beverage$4,009100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 47 | $1,500 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 28 | $547 |
| Medtronic(2 entities) | 12 | $426 |
| Flowonix Medical Incorporated | 1 | $362 |
| Nevro Corp. | 11 | $296 |
| Tersera Therapeutics LLC | 11 | $206 |
| Collegium Pharmaceutical, Inc. | 10 | $182 |
| Forte Bio-pharma LLC | 2 | $137 |
| Pfizer | 2 | $40 |
| Scilex Pharmaceuticals Inc. | 2 | $28 |
| Vertex | 1 | $28 |
| Bioventus LLC | 1 | $26 |
| Metacel Pharmaceuticals LLC | 1 | $21 |
| Protega Pharmaceutials Inc | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Boston Scientific | 1 | $18 |
| Baudax Bio Inc. | 1 | $18 |
| GRT US Holding, Inc. | 1 | $17 |
| Convatec Inc. | 1 | $17 |
| Sentynl Therapeutics, Inc. | 1 | $17 |
| AbbVie | 1 | $17 |
| Shionogi Inc | 1 | $14 |
| Biodelivery Sciences International, Inc. | 1 | $14 |
| Pacira Therapeutics, Inc. | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Redhill Biopharma Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prometra II$362
- Proclaim Family of SCS IPGs$314
- ETERNA$158
- PROCLAIM$128
How this compares
$4,009 in reported general payments places this provider in the 55th percentile of 38 interventional pain medicine providers in South Carolina.
See all interventional pain medicine providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxymorphone Hcl ErOxymorphone Hcl | 13 | $22,955 |
| OxycontinOxycodone Hcl | 26 | $13,618 |
| Oxycodone Hcl | 586 | $12,815 |
| Morphine Sulfate ErMorphine Sulfate | 186 | $12,662 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 334 | $9,396 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 207 | $5,403 |
| Methadone Hcl | 122 | $5,078 |
| Xtampza ErOxycodone Myristate | 15 | $4,850 |
| Gabapentin | 138 | $4,384 |
| Hydromorphone Hcl | 293 | $4,340 |
| Morphine Sulfate | 68 | $3,572 |
| Fentanyl | 20 | $1,937 |
| Celecoxib | 47 | $1,140 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 33 | $782 |
| Baclofen | 76 | $776 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $182 | $4,85015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 38 interventional pain medicine providers in South Carolina.
Other interventional pain medicine in Hilton Head
- Mark NethertonMt Pleasant$102K
- Marion McMillanSeneca$89K
- Jason RosenbergMurrells Inlet$82K
- Ryan NoblesMt Pleasant$43K
- Justin HutchesonGreenville$23K
- Joshua BighamSpartanburg$14K
- David RoweBluffton$9K
- William DurrettAiken$8K
- Kenneth GrosslightWest Columbia$7K
- Phillip SuwanAiken$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.